Stockscreener 앱 받기
56.37
5.81%
-3.55
전일 마감가:
$59.92
열려 있는:
$57.11
하루 거래량:
364.09K
Relative Volume:
0.38
시가총액:
$1.07B
수익:
$90.12M
순이익/손실:
$-276.06M
주가수익비율:
-38.61
EPS:
-1.46
순현금흐름:
$-193.47M
1주 성능:
-7.35%
1개월 성능:
-6.79%
6개월 성능:
+7,405%
1년 성능:
+4,144%
1일 변동 폭
$56.30
$58.51
1주일 범위
$56.30
$66.92
52주 변동 폭
$0.432
$66.92
넥타테라퓨틱스 Stock (NKTR) Company Profile
명칭
Nektar Therapeutics
전화
(415) 482-5300
주소
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
NKTR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
56.47 | 1.14B | 90.12M | -276.06M | -193.47M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
428.42 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
631.32 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
426.61 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
842.02 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.88 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
넥타테라퓨틱스 Stock (NKTR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-24 | 재확인 | BTIG Research | Buy |
| 2025-06-24 | 재확인 | H.C. Wainwright | Buy |
| 2025-04-11 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-03-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-01-08 | 개시 | B. Riley Securities | Buy |
| 2024-12-10 | 개시 | H.C. Wainwright | Buy |
| 2024-11-04 | 개시 | Piper Sandler | Overweight |
| 2024-09-30 | 재개 | BTIG Research | Buy |
| 2024-06-28 | 개시 | Rodman & Renshaw | Buy |
| 2023-11-20 | 재개 | JP Morgan | Underweight |
| 2023-11-09 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-05-10 | 업그레이드 | Jefferies | Underperform → Hold |
| 2023-02-24 | 다운그레이드 | Jefferies | Hold → Underperform |
| 2022-08-08 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-05-31 | 재개 | Jefferies | Hold |
| 2022-04-18 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-03-15 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2022-03-15 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-03-14 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2022-03-14 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-03-14 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-03-14 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-11-08 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-09-10 | 개시 | BofA Securities | Neutral |
| 2021-06-28 | 업그레이드 | Stifel | Hold → Buy |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-02-22 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-01-06 | 개시 | Stifel | Hold |
| 2020-09-14 | 개시 | JP Morgan | Neutral |
| 2020-06-10 | 다운그레이드 | CFRA | Hold → Sell |
| 2020-05-12 | 재확인 | H.C. Wainwright | Neutral |
| 2020-04-22 | 개시 | The Benchmark Company | Buy |
| 2020-03-30 | 업그레이드 | Goldman | Sell → Neutral |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-02-03 | 업그레이드 | Mizuho | Neutral → Buy |
| 2019-10-24 | 개시 | Oppenheimer | Perform |
| 2019-10-08 | 다운그레이드 | Goldman | Buy → Sell |
| 2019-08-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-08-09 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-08-09 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2019-03-15 | 개시 | SVB Leerink | Mkt Perform |
| 2018-12-13 | 개시 | Goldman | Buy |
| 2018-06-11 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | 재확인 | H.C. Wainwright | Buy |
| 2018-04-20 | 개시 | Seaport Global Securities | Buy |
| 2018-04-13 | 재개 | Piper Jaffray | Overweight |
| 2018-04-06 | 재확인 | Mizuho | Buy |
| 2018-04-02 | 재개 | H.C. Wainwright | Buy |
모두보기
넥타테라퓨틱스 주식(NKTR)의 최신 뉴스
Is it time to cut losses on Nektar TherapeuticsQuarterly Investment Review & Reliable Breakout Forecasts - newser.com
Why Nektar Therapeutics stock remains on buy lists2025 AllTime Highs & Verified Chart Pattern Trade Signals - newser.com
Can Nektar Therapeutics hit a new high this monthJuly 2025 News Drivers & Consistent Growth Stock Picks - newser.com
Is Nektar Therapeutics trending in predictive chart modelsJuly 2025 Closing Moves & Long-Term Capital Growth Strategies - newser.com
Is Nektar Therapeutics stock a good choice for value investorsMarket Sentiment Report & Weekly Setup with High ROI Potential - newser.com
Why retail investors pile into Nektar Therapeutics stockOil Prices & Verified Swing Trading Watchlist - newser.com
Pattern recognition hints at Nektar Therapeutics upsideGlobal Markets & Proven Capital Preservation Tips - newser.com
Published on: 2025-11-03 04:48:43 - newser.com
Why Nektar Therapeutics stock remains undervaluedJuly 2025 Outlook & Safe Capital Preservation Plans - newser.com
Will Nektar Therapeutics stock benefit from AI adoptionPortfolio Gains Summary & Community Consensus Picks - newser.com
Can Nektar Therapeutics (ITH0) stock sustain free cash flow2025 Price Momentum & AI Forecasted Entry and Exit Points - newser.com
What margin trends mean for Nektar Therapeutics stockJuly 2025 Trade Ideas & Capital Efficient Trading Techniques - newser.com
Using economic indicators to assess Nektar Therapeutics potential2025 Year in Review & Daily Momentum Trading Reports - newser.com
Moody Aldrich Partners LLC Invests $1.17 Million in Nektar Therapeutics $NKTR - MarketBeat
Will Nektar Therapeutics continue its uptrend2025 Analyst Calls & AI Driven Price Predictions - newser.com
Nektar Therapeutics (NKTR): Valuation Reset as REZOLVE-AD Phase 2b Data and Analyst Optimism Drive Investor Interest - simplywall.st
Is Nektar Therapeutics (ITH0) stock undervalued at current priceQuarterly Profit Report & Weekly Watchlist for Consistent Profits - newser.com
Nektar Therapeutics (NASDAQ:NKTR) Reaches New 1-Year HighShould You Buy? - MarketBeat
Is Nektar Therapeutics (ITH0) stock a top dividend aristocrat candidateJuly 2025 Gainers & Comprehensive Market Scan Reports - newser.com
Nektar Therapeutics stock hits 52-week high at 65.97 USD By Investing.com - Investing.com Australia
Nektar Therapeutics (NKTR) Is Up 8.0% After Late-Breaking Phase 2b Rezpegaldesleukin Data Announcement - Sahm
Nektar Therapeutics stock hits 52-week high at 65.97 USD - Investing.com
Best data tools to analyze Nektar Therapeutics stock2025 Market Trends & Detailed Earnings Play Strategies - newser.com
Nektar Therapeutics (NKTR): Taking a Fresh Look at Valuation After Recent Share Price Rebound - Yahoo Finance
Can volume confirm reversal in Nektar TherapeuticsJuly 2025 Update & Free Real-Time Market Sentiment Alerts - newser.com
Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London - PR Newswire
Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
Nektar Therapeutics $NKTR Holdings Trimmed by Deuterium Capital Management LLC - MarketBeat
Can Nektar Therapeutics stock resist market sell offsJuly 2025 Movers & Weekly High Return Opportunities - newser.com
넥타테라퓨틱스 (NKTR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.35%
0.35%
자본화:
|
볼륨(24시간):